Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | STK11 F354L |
| Therapy | Everolimus + Exemestane |
| Indication/Tumor Type | triple-receptor negative breast cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| STK11 F354L | triple-receptor negative breast cancer | predicted - sensitive | Everolimus + Exemestane | Case Reports/Case Series | Actionable | In a clinical case study, Afinitor (everolimus) in combination with Aromasin (exemestane) resulted in complete response ongoing for 14 months in a patient with metastatic triple-receptor negative breast cancer harboring STK11 F354L (PMID: 28550065). | 28550065 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (28550065) | Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an STK11 variant. | Full reference... |